The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
Open accessAbstract
Purpose: Romidepsin (depsipeptide or FK228) is a member of a new class of antineoplastic agents active in T-cell lymphoma, the histone deacetylase inhibitors. On the basis of observed responses in a phase I trial, a phase II trial of romidepsin in patients with T-cell lymphoma was initiated. Patients and Methods: The initial cohort was limited to patients with cutaneous T-cell lymphoma (CTCL), or subtypes mycosis fungoides or Sézary syndrome, who had received no more than two prior cytotoxic regimens. There were no limits on other types of therapy. Subsequently, the protocol was expanded to enroll patients who had received more than two prior cytotoxic regimens. Results: Twenty-seven patients were enrolled onto the first cohort, and a total of 71 patients are included in this analysis. These patients had undergone a median of four prior treatments, and 62 patients (87%) had advanced-stage disease (stage IIB, n = 15; stage III, n= 6; or stage IV, n = 41). Toxicities included nausea, vomiting, fatigue, and transient thrombocytopenia and granulocytopenia. Pharmacokinetics were evaluated with the first administration of romidepsin. Complete responses were observed in four patients, and partial responses were observed in 20 patients for an overall response rate of 34% (95% CI, 23% to 46%). The median duration of response was 13.7 months. Conclusion: The histone deacetylase inhibitor romidepsin has single-agent clinical activity with significant and durable responses in patients with CTCL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
Marks, P. A., Richon, V. M., & Rifkind, R. A. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1210 · Cited by 1,157
Olsen, E. A., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S., Frankel, S. R., Chen, C., Ricker, J. L., Arduino, J. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2434 · Cited by 1,055
Interaction of citrus juices with felodipine and nifedipine
Bailey, D., Spence, J., Munoz, C., & Arnold, J. M. O. (1991) · The Lancet · doi:10.1016/0140-6736(91)90872-m · Cited by 596
Peart, M. J., Smyth, G. K., van Laar, R. K., Bowtell, D. D., Richon, V. M., Marks, P. A., Holloway, A. J., & Johnstone, R. W. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500369102 · Cited by 539
p21 WAF1 is required for butyrate-mediated growth inhibition of human colon cancer cells
Archer, S. Y., Meng, S., Shei, A., & Hodin, R. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.6791 · Cited by 535
Incidence of Cutaneous T-Cell Lymphoma in the United States, 1973-2002
Criscione, V. D., & Weinstock, M. A. (2007) · Archives of Dermatology · doi:10.1001/archderm.143.7.854 · Cited by 527
Sandor, V. A., Bakke, S., Robey, R. W., Kang, M. H., Blagosklonny, M. V., Bender, J., Brooks, R. A., Piekarz, R., Tucker, E. E., Figg, W. D., et al. (2002) · PubMed · Cited by 502
Self-citationUEDA, H., NAKAJIMA, H., HORI, Y., FUJITA, T., NISHIMURA, M., GOTO, T., & OKUHARA, M. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.301 · Cited by 489
FR901228, a Potent Antitumor Antibiotic, Is a Novel Histone Deacetylase Inhibitor
Nakajima, H., Kim, Y. B., Terano, H., Yoshida, M., & Horinouchi, S. (1998) · Experimental Cell Research · doi:10.1006/excr.1998.4027 · Cited by 487
Histone deacetylase inhibitors in cancer therapy
Johnstone, R. W., & Licht, J. D. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00165-x · Cited by 449
Piekarz, R. L., Robey, R., Sandor, V., Bakke, S., Wilson, W. H., Dahmoush, L., Kingma, D. M., Turner, M. L., Altemus, R., & Bates, S. E. (2001) · Blood · doi:10.1182/blood.v98.9.2865 · Cited by 445
Self-citationSecond generation hybrid polar compounds are potent inducers of transformed cell differentiation.
Richon, V. M., Webb, Y., Merger, R., Sheppard, T., Jursic, B., Ngo, L., Civoli, F., Breslow, R., Rifkind, R. A., & Marks, P. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.5705 · Cited by 420
Immunopathogenesis and therapy of cutaneous T cell lymphoma
Kim, E. J., Hess, S., Richardson, S. K., Newton, S., Showe, L. C., Benoit, B. M., Ubriani, R., Vittorio, C. C., Junkins-Hopkins, J. M., Wysocka, M., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24826 · Cited by 413
Ellis, L., Pan, Y., Smyth, G. K., George, D. J., McCormack, C., Williams-Truax, R., Mita, M., Beck, J., Burris, H., Ryan, G., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4262 · Cited by 297
Self-citationPrognosis in cutaneous T-cell lymphoma by skin stage: Long-term survival in 489 patients
Zackheim, H. S., Amin, S., Kashani-Sabet, M., & McMillan, A. (1999) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(99)70491-3 · Cited by 294
Sandor, V, Senderowicz, A., Mertins, S., Sackett, D., Sausville, E., Blagosklonny, M. V., & Bates, S. E. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1327 · Cited by 290
Self-citationHistopathologic Staging at Initial Diagnosis of Mycosis Fungoides and the Sézary Syndrome
Sausville, E. A., Eddy, J. L., Makuch, R. W., Fischmann, A. B., Schechter, G. P., Matthews, M., GLATSTEIN, E. J., Ihde, D. C., Kaye, F., Veach, S. R., et al. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-109-5-372 · Cited by 268
Piekarz, R. L., Frye, A. R., Wright, J. J., Steinberg, S. M., Liewehr, D. J., Rosing, D. R., Sachdev, V., Fojo, T., & Bates, S. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2095 · Cited by 232
Self-citationInfections Complicating Mycosis Fungoides and Sézary Syndrome
Axelrod, P. I. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03480100060031 · Cited by 219
Systemic Therapy of Cutaneous T-Cell Lymphomas (Mycosis Fungoides and the Sezary Syndrome)
Bunn, P. A., Hoffman, S. J., Norris, D., Golitz, L. E., & Aeling, J. L. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-8-199410150-00007 · Cited by 214
A phase I trial of Depsipeptide (FR901228) in patients with advanced cancer
Marshall, J. L., Rizvi, N., Kauh, J., Dahut, W., Figuera, M., Kang, M. H., Figg, W. D., Wainer, I., Chaissang, C., Zhaoyang Li, M., et al. (2002) · Journal of Experimental Therapeutics and Oncology · doi:10.1046/j.1359-4117.2002.01039.x · Cited by 204
Self-citationA Review of Depsipeptide and Other Histone Deacetylase Inhibitors in Clinical Trials
Piekarz, R., & Bates, S. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043383980 · Cited by 174
Self-citationPrognostic factor analysis in mycosis fungoides/Sézary syndrome
Diamandidou, E., Colome, M., Fayad, L., Duvic, M., & Kurzrock, R. (1999) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(99)70079-4 · Cited by 172
TOKURA, Y., Yagi, H., Ohshima, A., KUROKAWA, S., Wakita, H., Yokote, R., Shirahama, S., FLIRUKAWA, F., & TAKIGAWA, M. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1995.tb02485.x · Cited by 90
The Sézary syndrome: hematologic criteria
Vonderheid, E. C., & Bernengo, M. G. (2003) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(03)00120-5 · Cited by 79
Woo, S., Gardner, E. R., Chen, X., Ockers, S. B., Baum, C. E., Sissung, T. M., Price, D. K., Frye, R., Piekarz, R., Bates, S. E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1215 · Cited by 71
Self-citationPiekarz, R., Sackett, D. L., & Bates, S. E. (2007) · The Cancer Journal · doi:10.1097/ppo.0b013e31803c73cc · Cited by 57
Self-citationShiraga, T., Tozuka, Z., Ishimura, R., Kawamura, A., & Kagayama, A. (2005) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.28.124 · Cited by 40
Cited by
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
Microtubule-binding agents: a dynamic field of cancer therapeutics
Dumontet, C., & Jordan, M. A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3253 · Cited by 1,718
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
Cancer epigenetics reaches mainstream oncology
Rodríguez-Paredes, M., & Esteller, M. (2011) · Nature Medicine · doi:10.1038/nm.2305 · Cited by 1,205
Natural products: An evolving role in future drug discovery
Mishra, B. B., & Tiwari, V. K. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.07.057 · Cited by 860
Metadata
- Authors
- Piekarz, R. L., Frye, R., Turner, M., Wright, J. J., Allen, S. L., Kirschbaum, M. H., Zain, J., Prince, H. M., Leonard, J. P., Geskin, L. J., Reeder, C., Joske, D., Figg, W. D., Gardner, E. R., Steinberg, S. M., Jaffe, E. S., Stetler-Stevenson, M., Lade, S., Fojo, A. T., & Bates, S. E.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-11-10
- Volume
- 27
- Issue
- 32
- Pages
- 5410-5417
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2156517973
- Cited by
- 740
- References
- 31
- FWCI
- 68.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.